New drug combo targets Hard-to-Treat cancers
NCT ID NCT03162627
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 37 times
Summary
This study tests a combination of two drugs, selumetinib and olaparib, in people with advanced or recurrent solid tumors (including breast, digestive, and reproductive organ cancers). The first phase finds the safest dose, and the second phase checks if that dose helps control the cancer. Up to 90 participants will take part at MD Anderson Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
selumetinib and olaparib (drug combination)
What this could lead to
If this works, it could offer a new treatment option for people with advanced or recurrent solid tumors that have not responded to standard therapies.
What could go wrong
This is an early phase 1 trial, so the main goal is finding a safe dose, not proving effectiveness. The combination may cause side effects and might not shrink tumors or extend survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.